Vasovist is indicated for contrast-enhanced magnetic resonance angiography for visualization of abdominal or limb vessels in patients with suspected or known vascular disease.
“This approval creates more positive momentum for our lead imaging product,” stated Andrew Uprichard, president of Epix Pharmaceuticals
In October 2005, the European Medicines Agency granted marketing approval of Vasovist for all 25 member states of the European Union. Vasovist has also been approved in Switzerland and Australia.
Epix also have upcoming clinical trial results for a treatment for generalized anxiety disorder, a new thrombus agent and the initiation of a trial of PRX-03140 with the drug Aricept in patients with Alzheimer’s disease.